Cargando…
Pembrolizumab-Induced Vitiligo in Esophageal Squamous Cell Carcinoma Patient With Durable Complete Response
Immune checkpoint inhibitors have emerged as a valuable therapeutic strategy in cancer treatment. Pembrolizumab is an inhibitor of programmed cell death protein 1 (PD-1) and its ligands 1 (PD-L1) and 2 (PD-L2). Disrupting the interaction between PD-L1 expressed on the cancer cell and PD-1 transmembr...
Autores principales: | Wilkins, Matthew C, Elgamal, Mohamed, Rybkin, Igor I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684827/ https://www.ncbi.nlm.nih.gov/pubmed/34938618 http://dx.doi.org/10.7759/cureus.19739 |
Ejemplares similares
-
Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab
por: Cristancho, Cagney, et al.
Publicado: (2020) -
Durable Complete Response to Pembrolizumab in Esophageal Squamous Cell Carcinoma With Divergent Microsatellite Status: A Case Report
por: Zeng, Tian, et al.
Publicado: (2021) -
Vitiligo-Associated Autoimmune Disorders: A Woman With Vitiligo and Incipient Hypothyroidism
por: Malik, Sara, et al.
Publicado: (2021) -
Vitiligo: A Narrative Review
por: Joge, Rutuja R, et al.
Publicado: (2022) -
Pembrolizumab-Induced Lichen Planus in a Patient With Non-Small-Cell Lung Carcinoma (NSCLC) That Correlates to Therapeutic Response
por: Sehbai, Aasim, et al.
Publicado: (2022)